PhaseRx polymers work by responding to the lower pH environment of the endosome and use a novel mechanism to effect passage of siRNA across the endosomal membrane and into the cytoplasm. The system uses natural cellular functions to enable endosome escape, can be targeted to specific cells, and is versatile, robust, reproducible and scalable.

The benefit of the PhaseRx RNAi delivery system is the ability to deliver RNAi therapeutics predictably to selected tissues in vivo, thereby unlocking the value of siRNA as a new therapeutic modality.

The PhaseRx delivery system is differentiated from other systems in its ability to mediate endosome escape, target specific cells, to be made reproducibly with controlled molecular architecture, and to be manufactured at scale.

The system overcomes many of the challenges sometimes associated with RNA delivery systems, such as poor intracellular delivery, immunogenicity and lack of developability such as regulatory hurdles associated with inconsistent product specifications.